News | Cath Lab | November 09, 2017

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

TherOx IC-HOT study meets primary endpoint for improved patient outcomes

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

November 9, 2017 — TherOx Inc. announced that results of its IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study successfully met its primary endpoint. The purpose of this study was to confirm the safety and effectiveness of Supersaturated Oxygen (SSO2) Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful percutaneous coronary intervention (PCI) with stenting within six hours of experiencing AMI symptoms. These results are included in the Premarket Approval (PMA) application for the SSO2 Therapy system that has been accepted for filing by the U.S. Food and Drug Administration (FDA).

The study results were presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

“Supersaturated oxygen is the only therapy shown in a pivotal randomized trial to reduce the important endpoint of infarct size in patients with large myocardial infarction,” said Gregg W. Stone, M.D., principal investigator of the IC-HOT study and professor of medicine at Columbia University Medical Center. “The IC-HOT study, using a simpler delivery method than previously tested, demonstrated that use of supersaturated oxygen is safe after successful primary stenting in high-risk patients with anterior myocardial infarction.”

IC-HOT is a confirmatory study of the second-generation TherOx system that delivers SSO2 Therapy for reduction of infarct size after an AMI. The study enrolled 100 patients at 15 investigational centers in the United States. IC-HOT results build on the successful outcome of the AMIHOT II controlled, randomized pivotal trial that studied the first-generation SSO2 Therapy system, and combined these study results to provide the FDA with the basis for PMA approval.

SSO2 Therapy is intended to provide interventional cardiologists with the first treatment option beyond PCI to salvage heart muscle in heart attack patients. Although PCI is the standard of care in treating AMI, for many patients it does not sufficiently reduce infarct size to achieve maximum clinical benefit. In SSO2 Therapy, the patient’s blood is supersaturated with oxygen and then returned directly to the targeted ischemic area of the heart through a small catheter. Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size.

Find links to articles and videos for all the key presentations in the article "TCT 2017 Late-breaking Clinical Trial Presentations."
 

 

For more information: www.therox.com

Related Content

Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.